COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,537 Articles (22,881 medRxiv, 8,656 bioRxiv)

Most recent first Previous |  Page 1069: Articles 10681-10690  | Next

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium
Drawz, P. E., DeSilva, M., Bodurtha, P., Vazquez Benitez, G., Murray, A., Chamberlain, A. M., Dudley, R. A., Waring, S., Kharbanda, A. B., Murphy, D., Muscoplat, M. H., Melendez, V., Margolis, K. L., McFarling, L., Lupu, R., Winkelman, T. N. A., Johnson, S.
10.1101/2021.12.23.21267853 — Posted: 2021-12-25
Healthcare workers' COVID-19 Omicron variant uncertainty-related stress, resilience, and coping strategies during the first week of World Health Organization alert
Temsah, M.-H., Alenezi, S., Al-Arabi, M., Aljamaan, F., Alhasan, K., Assiri, R., Bassrawi, R., Alshahrani, F., Alhaboob, A., Alaraj, A., Alharbi, N. S., Halwani, R., Jamal, A., Abdulmajeed, N., Alfarra, L., almashdali, W., Al-Eyadhy, A., AlZamil, F., Al-Subaie, S., Barry, M., Memish, Z. A., Al-Tawfiq, J. A.
10.1101/2021.12.24.21268377 — Posted: 2021-12-24
SARS-CoV-2 vaccine Alpha and Delta variant breakthrough infections are rare and mild, but happen relative early after vaccination
Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., Seth-Smith, H. M. B., Scotton, P., Redondo, M., Beckmann, C., Stadler, T., Salzmann, A., Kurth, H., Leuzinger, K., Bassetti, S., Bingisser, R., Siegemund, M., Weisser, M., Battegay, M., Tschudin Sutter, S., Lebrand, A., Hirsch, H. H., Fuchs, S., Egli, A.
10.1101/2021.12.23.21268324 — Posted: 2021-12-24
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
Weber, S., Kehl, V., Erber, J., Wagner, K. I., Jetzlsperger, A.-M., Burrell, T., Schober, K., Schommers, P., Augustin, M., Crowell, C. S., Gerhard, M., Winter, C., Spinner, C. D., Protzer, U., Hoffmann, D., DIppolito, E., Busch, D.
10.1101/2021.12.22.21268268 — Posted: 2021-12-24
Essential Workers COVID-19 Vaccine Hesitancy, Misinformation and Informational Needs in the Republic of North Macedonia.
Fucaloro, S., Yacoubian, V., Harriman, N., Pitch-Loeb, R., Hadji-Janev, M., Savoia, E.
10.1101/2021.12.22.21268045 — Posted: 2021-12-24
Early Treatment with fluvoxamine among patients with COVID-19: a cost-consequence model
Mills, F. P., Reis, G., Thorlund, K., Forrest, J. I., Guo, C. M., Boulware, D. R., Mills, E. J.
10.1101/2021.12.23.21268352 — Posted: 2021-12-24
Tracking community infection dynamics of COVID-19 by monitoring SARS-CoV-2 RNA in wastewater, counting positive reactions by qPCR
Zhao, B., Yu, Z., Fujita, T., Nihei, Y., Tanaka, H., Ihara, M.
10.1101/2021.12.23.21268343 — Posted: 2021-12-24
Change in COVID-19 risk over time following vaccination with CoronaVac: A test-negative case-control study
Hitchings, M., Ranzani, O., Lind, M. L., Dorion, M., D'Agostini, T. L., Cardoso de Paula, R., Pereira de Paula, O. F., Moura de Villela, E. F., Scaramuzzini Torres, M. S., Barbosa de Oliveira, S., Schulz, W., Almiron, M., Said, R., de Oliveira, R. D., da Silva, P. V., de Araujo, W. N., Gorinchteyn, J. C., Dean, N. E., Andrews, J. R., Cummings, D. A., Ko, A. I., Croda, J.
10.1101/2021.12.23.21268335 — Posted: 2021-12-24
Population immunity to SARS-CoV-2 in US states and counties due to infection and vaccination, January 2020-November 2021
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., Menzies, N. A.
10.1101/2021.12.23.21268272 — Posted: 2021-12-24
Sharp Increases in Drug Overdose Deaths Among High-School-Age Adolescents During the US COVID-19 Epidemic and Illicit Fentanyl Crisis
Friedman, J., Godvin, M., Shover, C., Gone, J. P., Hansen, H., Schriger, D.
10.1101/2021.12.23.21268284 — Posted: 2021-12-24 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).